(Length of Discussion: 10 min)

Daniel George and Martin Voss discuss the evolving management of patients with advanced renal cell carcinoma with a focus on the genomic landscape in high risk localized disease. Based on molecular profiles, we may be able to prognosticate more accurately on their risk for recurrence. Applicability of this biomarker data will guide the future in appropriate therapeutic choices.

Biographies:

Martin H. Voss, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center

Daniel George, MD

Referenced in this discussion:

Adjuvant sunitinib in patients with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial